Timothy Radstake, M.D. and Ph.D., attended medical school at the Radboud University, Nijmegen, The Netherlands, where he graduated in 2000 with the judicium Cum Laude. He next performed his Ph.D. on the genetic factors that determine the susceptibility to rheumatoid arthritis and the role of dendritic cells in this conditions that he finished in 2003 (Cum Laude). Soon after that, Radstake developed his own research group focusing on the role of toll-like receptors (TLRs) and Fc gamma receptors in the regulation of dendritic cells function in rheumatoid arthritis. His group stood at the basis of the observation that TLRs play a role in arthritis by dysregulating DC and macrophage function. Over the years, Radstake's group investigated a broader spectrum of rheumatic conditions including psoriatic arthritis and systemic sclerosis. From 2007 to 2008, Radstake did a postdoctoral fellowship at the Department of Rheumatology, Boston University School of Medicine (Professor R. Lafyatis) where he currently still holds a position as an Associate Professor in systemic sclerosis. From March 2012, he has been serving as a Full Chair in translational immunology at the University Medical Center Utrecht where his research team comprising 8 postdocs and 12 Ph.D. students focuses on immune aspects of a broad spectrum of immune-mediated diseases including SLE, Sjogren’s syndrome, RA, PsA, systemic sclerosis, and inflammatory myopathies. Together with Professor B. Prakken and Dr. M. Boes, he is heading the clinical research line within the Laboratory of Translational Immunology encompassing ~ 80 fte working on translational immunology. His major aim is to understand how (epi)genetic alterations lead to immune dysregulation in immune-mediated diseases and fibrosis. Ultimately, he is leading the effort to develop therapeutic targets to these conditions based on the genetic/epigenetic aberrances that are patient specific (patient-tailored medicine).
Biography Updated on 27 June 2013